María Ángeles
Castro Iglesias
Profesora Titular de Universidad
Hospital Juan Ramón Jiménez
Huelva, EspañaPublicaciones en colaboración con investigadores/as de Hospital Juan Ramón Jiménez (6)
2017
-
Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253
2015
-
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784
2005
-
Molecular epidemiology of HTLV-2 infection among intravenous drug users in Spain
Journal of Clinical Virology, Vol. 33, Núm. 1, pp. 65-70
2001
-
Multicenter randomized study comparing initial daily induction with high dose lymphoblastoid interferon vs. standard interferon treatment for chronic hepatitis C
Journal of Medical Virology, Vol. 64, Núm. 4, pp. 460-465
1997
-
Multicenter randomized, controlled study of intramuscular administration of interferon-β for the treatment of chronic hepatitis C
Journal of Interferon and Cytokine Research, Vol. 17, Núm. 1, pp. 27-30
-
Tolerance and efficacy of subcutaneous interferon-β administered for treatment of chronic hepatitis C
Journal of Interferon and Cytokine Research, Vol. 17, Núm. 2, pp. 65-67